Baxter Enters Agreement to Divest Vero Cell Vaccines Platform
Baxter announced that it had entered into an agreement to sell its Vero cell technology and related assets to Nanotherapeutics.
Baxter International announced on Dec. 15, 2014 that it had entered into an agreement with Nanotherapeutics to divest Vero cell technology, related assets, and its production facility in Bohumil, Czech Republic. The assets divested as part of the agreement include the vaccines for H5N1, H1N1, the seasonal flu, and investigational vaccines for Ross River virus, Chikungunya disease, and West Nile virus. Vero cell platform is a cell-based technology for vaccine production.
"The divestiture of the vaccines franchise will allow Baxter BioScience to enhance focus in core therapeutic areas of hematology, oncology, and immunology, as it prepares to become an independent biopharmaceutical company,” said Ludwig Hantson, PhD, president of Baxter BioScience, in a press release.
Source: Baxter
